The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies

被引:37
作者
Zivny, J. [1 ,2 ]
Klener, P., Jr. [1 ,2 ,3 ,4 ]
Pytlik, R. [3 ,4 ]
Andera, L. [5 ]
机构
[1] Charles Univ Prague, Inst Pathol Physiol, Fac Med 1, Prague 12853 2, Czech Republic
[2] Charles Univ Prague, Ctr Expt Hematol, Fac Med 1, Prague 12853 2, Czech Republic
[3] Charles Univ Prague, Dept Med 1, Dept Clin Haematol, Fac Med 1, Prague 12853 2, Czech Republic
[4] Charles Univ Prague, Gen Teaching Hosp, Prague 12853 2, Czech Republic
[5] Czech Acad Sci, Inst Mol Genet, Lab Cell Signaling & Apoptosis, Prague, Czech Republic
关键词
Cancer; leukemia; lymphoma; apoptosis; hematology; TUMOR-NECROSIS-FACTOR; CHRONIC LYMPHOCYTIC-LEUKEMIA; PROTEIN-KINASE-C; ACUTE MYELOID-LEUKEMIA; BCL-2 ANTISENSE OLIGONUCLEOTIDE; NF-KAPPA-B; HISTONE DEACETYLASE INHIBITOR; ENDOPLASMIC-RETICULUM CA2+; SUBEROYLANILIDE HYDROXAMIC ACID; FARNESYL TRANSFERASE INHIBITOR;
D O I
10.2174/138161210789941883
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Apoptosis is a normal aspect of human physiology ensuring tissue homeostasis. Evasion of endogenous cell death processes, including apoptosis, represents one of the characteristics of cancer. Defects in the physiological mechanisms of apoptosis contribute to the pathological cell expansion and to the development and progression of cancer. Resistance of malignant cells to cancer therapeutic agents may be, in some cases, caused by dysregulation of apoptotic pathways, e. g. BCL2 or IAP overexpression. The understanding of the physiological mechanisms that control apoptosis and the elucidation of apoptotic defects in cancer cells may lead to the development of targeted cancer therapies. Apoptotic pathways, molecules involved in the cross-talk between individual apoptosis pathways and promising new anti-cancer agents, which trigger directly or indirectly apoptosis of hematologic cancer cells, are reviewed in this article.
引用
收藏
页码:11 / 33
页数:23
相关论文
共 356 条
[1]  
Alas S, 2003, CLIN CANCER RES, V9, P316
[2]  
Alas S, 2001, CLIN CANCER RES, V7, P709
[3]   A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival [J].
Alvi, AJ ;
Austen, B ;
Weston, VJ ;
Fegan, C ;
MacCallum, D ;
Gianella-Borradori, A ;
Lane, DP ;
Hubank, M ;
Powell, JE ;
Wei, WB ;
Taylor, AMR ;
Moss, PAH ;
Stankovic, T .
BLOOD, 2005, 105 (11) :4484-4491
[4]   Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma [J].
Amaravadi, Ravi K. ;
Yu, Duonan ;
Lum, Julian J. ;
Bui, Thi ;
Christophorou, Maria A. ;
Evan, Gerard I. ;
Thomas-Tikhonenko, Andrei ;
Thompson, Craig B. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (02) :326-336
[5]   A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J].
Ambrosini, G ;
Adida, C ;
Altieri, DC .
NATURE MEDICINE, 1997, 3 (08) :917-921
[6]   Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting [J].
Ambrosini, G ;
Adida, C ;
Sirugo, G ;
Altieri, DC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (18) :11177-11182
[7]   Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress [J].
Amundson, SA ;
Myers, TG ;
Fornace, AJ .
ONCOGENE, 1998, 17 (25) :3287-3299
[8]   Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma [J].
Aoki, Y ;
Feldman, GM ;
Tosato, G .
BLOOD, 2003, 101 (04) :1535-1542
[9]   Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta [J].
Apperley, JF ;
Gardembas, M ;
Melo, JV ;
Russell-Jones, R ;
Bain, BJ ;
Baxter, J ;
Chase, A ;
Chessells, JM ;
Colombat, M ;
Dearden, CE ;
Dimitrijevic, S ;
Mahon, FX ;
Marin, D ;
Nikolova, Z ;
Olavarria, E ;
Silberman, S ;
Schultheis, B ;
Cross, NCP ;
Goldman, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :481-487
[10]   Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization [J].
Arnoult, D ;
Gaume, B ;
Karbowski, M ;
Sharpe, JC ;
Cecconi, F ;
Youle, RJ .
EMBO JOURNAL, 2003, 22 (17) :4385-4399